Optimizing Anthem (Elevance Health) Biktarvy Prior Authorization Workflows

Navigating Anthem (Elevance Health) Biktarvy prior authorization requires precise understanding of payer-specific channels and clinical criteria to ensure timely patient access to essential HIV-1 therapy.

For revenue cycle directors and prior authorization teams, managing high-volume drug PAs like Biktarvy under Anthem-licensed plans presents unique operational challenges. Klivira provides the automation and connectivity to integrate with Anthem's diverse submission channels, reducing manual burden and accelerating decision cycles. This guide details the specific requirements for Biktarvy PA with Anthem (Elevance Health).

Biktarvy: Clinical Context and Prior Authorization Imperatives

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a widely prescribed single-tablet regimen for HIV-1 treatment. As a high-cost specialty medication, it is consistently subject to prior authorization requirements across commercial, Medicare Advantage, and Medicaid managed care plans operating under the Anthem (Elevance Health) umbrella. Efficient PA management is critical to maintain continuity of care for patients with HIV-1.

Anthem's Prior Authorization Channels for Biktarvy

**Pharmacy Benefit ePA**: For Biktarvy, typically covered under the pharmacy benefit, submissions are primarily facilitated through industry-standard ePA platforms like CoverMyMeds and Surescripts, integrating directly with prescriber EHRs.
**CarelonRx Provider Portal**: Direct submission is available through the CarelonRx provider portal, Elevance Health's in-house PBM, for plans serviced by this PBM.
**Medical Benefit Considerations**: While Biktarvy is primarily a pharmacy benefit drug, some specialty injectables and infusions on the medical benefit under Anthem may route through Availity for medical PA or Carelon Medical Benefits Management for specific categories.

Accessing Anthem's Utilization Management Criteria for Biktarvy

**Anthem Provider Portals**: Clinical criteria for Biktarvy, including formulary tiers, step therapy protocols, and quantity limits, are published by Anthem-licensed plans and are accessible via their provider websites, often surfaced through Availity Essentials.
**CarelonRx Resources**: Specific pharmacy benefit criteria, including formulary status and step therapy for Biktarvy, are maintained and published by CarelonRx.
**Policy Verification**: Always reference the specific policy number, plan-state context, and effective date to ensure compliance with the most current requirements.

Electronic Prior Authorization (ePA) Posture for Pharmacy Benefit Drugs

**CoverMyMeds & Surescripts**: These ePA platforms are key partners for CarelonRx, enabling prescribers to initiate Biktarvy prior authorization requests electronically, streamlining workflows.
**Da Vinci Project Engagement**: Elevance Health has participated in Da Vinci Project initiatives and HL7 connectathons, signaling a strategic alignment with FHIR standards for broader electronic data exchange, though specific production conformance for all domains requires verification.
**X12 278**: While primarily utilized for medical benefit services, Anthem operating companies do accept X12 278 transactions via clearinghouses for impacted procedures, demonstrating broader electronic transaction support.

Common Denial Reasons and Appeal Pathways for Biktarvy with Anthem

**Medical Necessity / Insufficient Documentation**: Denials often occur due to a lack of clinical justification or missing supporting lab results and chart notes.
**Step Therapy Not Completed**: Failure to document a trial and failure of a preferred alternative medication as mandated by the formulary is a frequent denial reason.
**Non-Formulary Drug**: Biktarvy may not be on the plan's preferred formulary, necessitating an exception request.
**Appeal Process**: Standard appeals for pharmacy benefit denials are managed through the Anthem operating company's process, with peer-to-peer review options available for clinical disputes.

Prior Authorization Turnaround Times and Regulatory Compliance

**State-Specific Mandates**: Commercial prior authorization timeframes for Anthem-licensed plans are governed by the state insurance regulations applicable to the state of the BCBS license, which vary materially.
**CMS-0057-F**: Anthem's Medicare Advantage and Medicaid managed care plans (including the Wellpoint subsidiary brand) are impacted payers under CMS-0057-F, subject to 72-hour standard and 24-hour expedited PA decision timeframes on the phased compliance timeline.
**Payer-Published Targets**: Anthem publishes precertification turnaround commitments through its provider portal; these should be verified for current service-level targets at each review cycle.

Frequently asked questions

How do I submit a prior authorization request for Biktarvy to Anthem (Elevance Health)?

For Biktarvy, typically a pharmacy benefit drug, submissions are primarily handled through CarelonRx. You can use industry-standard ePA platforms like CoverMyMeds or Surescripts, or submit directly via the CarelonRx provider portal.

Where can I find the specific clinical criteria for Biktarvy PA with Anthem?

Clinical criteria, including formulary details and step therapy requirements, are available on the Anthem operating company's provider portals (often accessed via Availity) or directly through the CarelonRx provider system. Always verify the policy number, state plan, and effective date.

What are common reasons for Biktarvy PA denials from Anthem?

Frequent denial reasons include insufficient documentation of medical necessity, failure to complete required step therapy, or the drug not being on the plan's preferred formulary. Addressing these points proactively can improve approval rates.

Does Anthem support electronic prior authorization for Biktarvy?

Yes, Anthem (through CarelonRx) strongly supports ePA for pharmacy benefit drugs like Biktarvy via partnerships with platforms such as CoverMyMeds and Surescripts, streamlining the submission process directly from the prescriber's EHR.

Are Anthem's Biktarvy PA turnaround times affected by CMS-0057-F?

Yes, for Biktarvy prior authorizations submitted to Anthem's Medicare Advantage and Medicaid managed care plans, the decision timeframes are impacted by CMS-0057-F, mandating 72-hour standard and 24-hour expedited reviews. Commercial lines are not directly impacted by this federal rule.